Business plan: antimalarial solutions

• Autor(a) principal: Lopes, Nuno Guerra
• Data de Publicação: 2016
• Tipo de documento: Dissertação
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10071/12427
• topic: Biotechnology; Pharmaceutical industry; New product development; Malaria; Biotecnologia; Indústria farmacêutica; Desenvolvimento de novos produtos

Malaria is an infectious disease that have caused huge losses to the human being, mainly for those who live in malaria endemic regions. In one hand, public entities spend millions in methods to avoid the transmission, in the treatment of infected people or in the eradication of the disease. In the other hand, half of the human population is at risk and there is half million deaths yearly, being considered one of the most dangerous diseases. Additionally to those who live in endemic regions, millions of travellers visit endemic regions yearly, causing an increase of the problem. As follows, the awareness around this infectious disease has been increasing, mainly due to the increase of the tourism around the world. The incorrect use of the existing medicines has induced to increasing the parasite resistance, reducing the efficiency of those medicines. In this way, it is imperative the development and launching of new medicines that could solve this problem. This problem was detected and both pharmaceutical companies and other entities are increasing their efforts in research and development, in order to find new antimalarial medicines that may decrease the malaria burden. However, the investment needed to the development of new medicines is excessively high, which means that not all the companies and entities are capable of performing those activities. Considering what was said above, the main objective of this Business Plan is to analyse the economic and financial viability of the development of a new antimalarial medicine.